BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cantuaria G, Magalhaes A, Penalver M, Angioli R, Braunschweiger P, Gomez-Marin O, Kanhoush R, Gomez-Fernandez C, Nadji M. Expression of GLUT-1 glucose transporter in borderline and malignant epithelial tumors of the ovary. Gynecol Oncol. 2000;79:33-37. [PMID: 11006027 DOI: 10.1006/gyno.2000.5910] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Iida T, Yasuda M, Miyazawa M, Fujita M, Osamura RY, Hirasawa T, Muramatsu T, Murakami M, Saito K, Mikami M. Hypoxic status in ovarian serous and mucinous tumors: relationship between histological characteristics and HIF-1alpha/GLUT-1 expression. Arch Gynecol Obstet 2008;277:539-46. [PMID: 18026974 DOI: 10.1007/s00404-007-0500-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
2 Zambrano A, Molt M, Uribe E, Salas M. Glut 1 in Cancer Cells and the Inhibitory Action of Resveratrol as A Potential Therapeutic Strategy. Int J Mol Sci 2019;20:E3374. [PMID: 31324056 DOI: 10.3390/ijms20133374] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 18.0] [Reference Citation Analysis]
3 Cai Y, Zhai JJ, Feng BB, Duan XZ, He XJ. Expression of glucose transporter protein 1 and p63 in serous ovarian tumor. J Obstet Gynaecol Res 2014;40:1925-30. [PMID: 25056472 DOI: 10.1111/jog.12447] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
4 Fischerova D, Burgetova A. Imaging techniques for the evaluation of ovarian cancer. Best Practice & Research Clinical Obstetrics & Gynaecology 2014;28:697-720. [DOI: 10.1016/j.bpobgyn.2014.04.006] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
5 Yoshida Y, Kurokawa T, Tsujikawa T, Okazawa H, Kotsuji F. Positron emission tomography in ovarian cancer: 18F-deoxy-glucose and 16alpha-18F-fluoro-17beta-estradiol PET. J Ovarian Res. 2009;2:7. [PMID: 19527525 DOI: 10.1186/1757-2215-2-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
6 Szablewski L. Expression of glucose transporters in cancers. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2013;1835:164-9. [DOI: 10.1016/j.bbcan.2012.12.004] [Cited by in Crossref: 130] [Cited by in F6Publishing: 203] [Article Influence: 16.3] [Reference Citation Analysis]
7 Shibata K, Kajiyama H, Mizokami Y, Ino K, Nomura S, Mizutani S, Terauchi M, Kikkawa F. Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia. Gynecologic Oncology 2005;98:11-8. [DOI: 10.1016/j.ygyno.2005.03.043] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
8 Mendez LE, Manci N, Cantuaria G, Gomez-marin O, Penalver M, Braunschweiger P, Nadji M. Expression of Glucose Transporter-1 in Cervical Cancer and Its Precursors. Gynecologic Oncology 2002;86:138-43. [DOI: 10.1006/gyno.2002.6745] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 1.9] [Reference Citation Analysis]
9 Baczewska M, Bojczuk K, Kołakowski A, Dobroch J, Guzik P, Knapp P. Obesity and Energy Substrate Transporters in Ovarian Cancer-Review. Molecules 2021;26:1659. [PMID: 33809784 DOI: 10.3390/molecules26061659] [Reference Citation Analysis]
10 Laïque S, Egrise D, Monclus M, Schmitz F, Garcia C, Lemaire C, Luxen A, Goldman S. L-Amino acid load to enhance PET differentiation between tumor and inflammation: anin vitro study on18F-FET uptake. Contrast Media Mol Imaging 2006;1:212-20. [DOI: 10.1002/cmmi.107] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
11 Shin SJ, Kim JY, Kwon SY, Mun K, Cho CH, Ha E. Ciglitazone enhances ovarian cancer cell death via inhibition of glucose transporter-1. European Journal of Pharmacology 2014;743:17-23. [DOI: 10.1016/j.ejphar.2014.09.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
12 Fujita M, Yasuda M, Kitatani K, Miyazawa M, Hirabayashi K, Takekoshi S, Iida T, Hirasawa T, Murakami M, Mikami M. An up-to-date anti-cancer treatment strategy focusing on HIF-1alpha suppression: its application for refractory ovarian cancer. Acta Histochem Cytochem. 2007;40:139-142. [PMID: 18224245 DOI: 10.1267/ahc.07024] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
13 Cantuaria G, Fagotti A, Ferrandina G, Magalhaes A, Nadji M, Angioli R, Penalver M, Mancuso S, Scambia G. GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy. Cancer 2001;92:1144-50. [PMID: 11571727 DOI: 10.1002/1097-0142(20010901)92:5<1144::aid-cncr1432>3.0.co;2-t] [Cited by in Crossref: 100] [Cited by in F6Publishing: 44] [Article Influence: 5.0] [Reference Citation Analysis]
14 Grahek D, Barranger E, Daraï E, Uzan S, Talbot J. Intérêt de la tomographie par émission de positons au [18F]-fluorodésoxyglucose dans le diagnostic, le bilan d'extension et la recherche de récidive des cancers gynécologiques et mammaires. Gynécologie Obstétrique & Fertilité 2005;33:371-81. [DOI: 10.1016/j.gyobfe.2005.01.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
15 Xintaropoulou C, Ward C, Wise A, Queckborner S, Turnbull A, Michie CO, Williams ARW, Rye T, Gourley C, Langdon SP. Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatment. BMC Cancer 2018;18:636. [PMID: 29866066 DOI: 10.1186/s12885-018-4521-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
16 Rakheja D, Khokhar S, Mitui M, Cost NG. Immunohistochemical expression of GLUT1 and its correlation with unfavorable histology and TP53 codon 72 polymorphism in Wilms tumors. Pediatr Dev Pathol 2012;15:286-92. [PMID: 22483234 DOI: 10.2350/12-01-1151-OA.1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
17 Brunetti J. PET/CT in Gynecologic Malignancies. Radiologic Clinics of North America 2013;51:895-911. [DOI: 10.1016/j.rcl.2013.05.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
18 Tyagi K, Mandal S, Roy A. Recent advancements in therapeutic targeting of the Warburg effect in refractory ovarian cancer: A promise towards disease remission. Biochim Biophys Acta Rev Cancer 2021;1876:188563. [PMID: 33971276 DOI: 10.1016/j.bbcan.2021.188563] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Zhao FQ, Keating AF. Functional properties and genomics of glucose transporters. Curr Genomics. 2007;8:113-128. [PMID: 18660845 DOI: 10.2174/138920207780368187] [Cited by in Crossref: 350] [Cited by in F6Publishing: 310] [Article Influence: 35.0] [Reference Citation Analysis]
20 Kueck A, Opipari AW, Griffith KA, Tan L, Choi M, Huang J, Wahl H, Liu JR. Resveratrol inhibits glucose metabolism in human ovarian cancer cells. Gynecologic Oncology 2007;107:450-7. [DOI: 10.1016/j.ygyno.2007.07.065] [Cited by in Crossref: 93] [Cited by in F6Publishing: 89] [Article Influence: 6.6] [Reference Citation Analysis]
21 Doss DM, Nirmal M, Veeravarmal, Saravanan R, Venkatesh A. Evaluating the expression of GLUT-1 in oral leukoplakia. J Oral Maxillofac Pathol 2020;24:308-14. [PMID: 33456240 DOI: 10.4103/jomfp.JOMFP_220_17] [Reference Citation Analysis]
22 Kurokawa T, Yoshida Y, Kawahara K, Tsuchida T, Okazawa H, Fujibayashi Y, Yonekura Y, Kotsuji F. Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer. 2004;109:926-932. [PMID: 15027127 DOI: 10.1002/ijc.20057] [Cited by in Crossref: 124] [Cited by in F6Publishing: 107] [Article Influence: 7.3] [Reference Citation Analysis]
23 Airley R, Evans A, Mobasheri A, Hewitt SM. Glucose transporter Glut-1 is detectable in peri-necrotic regions in many human tumor types but not normal tissues: Study using tissue microarrays. Ann Anat 2010;192:133-8. [PMID: 20395120 DOI: 10.1016/j.aanat.2010.03.001] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
24 Park S, Kim TS, Lim MC, Seo SS, Kang S, Kim SK, Yoo CW, Park SY. Glycolytic phenotypes in an evaluation of ovarian carcinoma based on carcinogenesis and BRCA mutation. Eur J Radiol 2020;133:109391. [PMID: 33171356 DOI: 10.1016/j.ejrad.2020.109391] [Reference Citation Analysis]
25 Airley RE, Mobasheri A. Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy 2007;53:233-56. [PMID: 17595539 DOI: 10.1159/000104457] [Cited by in Crossref: 228] [Cited by in F6Publishing: 216] [Article Influence: 16.3] [Reference Citation Analysis]
26 Cho H, Lee YS, Kim J, Chung JY, Kim JH. Overexpression of glucose transporter-1 (GLUT-1) predicts poor prognosis in epithelial ovarian cancer. Cancer Invest. 2013;31:607-615. [PMID: 24164300 DOI: 10.3109/07357907.2013.849722] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 5.5] [Reference Citation Analysis]
27 Rendic S, Guengerich FP. Update information on drug metabolism systems--2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters. Curr Drug Metab 2010;11:4-84. [PMID: 20302566 DOI: 10.2174/138920010791110917] [Cited by in Crossref: 76] [Cited by in F6Publishing: 64] [Article Influence: 6.9] [Reference Citation Analysis]
28 Karantanis D, Allen-auerbach M, Czernin J. Relationship Among Glycolytic Phenotype, Grade, and Histological Subtype in Ovarian Carcinoma. Clinical Nuclear Medicine 2012;37:49-53. [DOI: 10.1097/rlu.0b013e3182291e03] [Cited by in Crossref: 23] [Cited by in F6Publishing: 5] [Article Influence: 2.6] [Reference Citation Analysis]
29 Ashton-Sager A, Paulino AF, Afify AM. GLUT-1 is preferentially expressed in atypical endometrial hyperplasia and endometrial adenocarcinoma. Appl Immunohistochem Mol Morphol 2006;14:187-92. [PMID: 16785788 DOI: 10.1097/01.pai.0000162003.43334.c7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
30 Hong R, Lim SC. 18F-fluoro-2-deoxyglucose uptake on PET CT and glucose transporter 1 expression in colorectal adenocarcinoma. World J Gastroenterol 2012; 18(2): 168-174 [PMID: 22253523 DOI: 10.3748/wjg.v18.i2.168] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
31 Semaan A, Munkarah AR, Arabi H, Bandyopadhyay S, Seward S, Kumar S, Qazi A, Hussein Y, Morris RT, Ali-Fehmi R. Expression of GLUT-1 in epithelial ovarian carcinoma: correlation with tumor cell proliferation, angiogenesis, survival and ability to predict optimal cytoreduction. Gynecol Oncol 2011;121:181-6. [PMID: 21167567 DOI: 10.1016/j.ygyno.2010.11.019] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 3.6] [Reference Citation Analysis]
32 Lutz AM, Ray P, Willmann JK, Drescher C, Gambhir SS. 2-deoxy-2-[F-18]fluoro-D-glucose accumulation in ovarian carcinoma cell lines. Mol Imaging Biol 2007;9:260-6. [PMID: 17610017 DOI: 10.1007/s11307-007-0105-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
33 Matsuura T, Otsuka I, Ouchi T, Ouchi E, Asano R, Miyasaka N. Pretreatment maximum standardized uptake value in 18F-fluorodeoxyglucose positron emission tomography-computed tomography as a prognostic factor for ovarian clear cell carcinoma and low-grade serous carcinoma. Taiwan J Obstet Gynecol 2021;60:305-10. [PMID: 33678332 DOI: 10.1016/j.tjog.2021.01.009] [Reference Citation Analysis]
34 Martinez-Outschoorn UE, Balliet RM, Lin Z, Whitaker-Menezes D, Howell A, Sotgia F, Lisanti MP. Hereditary ovarian cancer and two-compartment tumor metabolism: epithelial loss of BRCA1 induces hydrogen peroxide production, driving oxidative stress and NFκB activation in the tumor stroma. Cell Cycle. 2012;11:4152-4166. [PMID: 23047606 DOI: 10.4161/cc.22226] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 3.9] [Reference Citation Analysis]
35 Abouzeid AH, Patel NR, Rachman IM, Senn S, Torchilin VP. Anti-cancer activity of anti-GLUT1 antibody-targeted polymeric micelles co-loaded with curcumin and doxorubicin. J Drug Target 2013;21:994-1000. [PMID: 24098980 DOI: 10.3109/1061186X.2013.840639] [Cited by in Crossref: 38] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
36 Lee YY, Choi CH, Kim CJ, Song TJ, Kim MK, Kim TJ, Lee JW, Kim BG, Lee JH, Bae DS. Glucose as a prognostic factor in non-diabetic women with locally advanced cervical cancer (IIB-IVA). Gynecol Oncol 2010;116:459-63. [PMID: 20004008 DOI: 10.1016/j.ygyno.2009.11.016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]